Weight Regain Following Discontinuation of GLP-1 Therapy

An important limitation emerging from current research on GLP-1 receptor agonists is the tendency for weight regain following treatment discontinuation. While these medications can produce substantial weight reduction during active therapy, maintaining those reductions once pharmacological support is removed remains a significant challenge.

Evidence suggests that the weight-reducing effects of GLP-1 therapies are primarily driven by ongoing neuroendocrine modulation of appetite and satiety pathways rather than permanent metabolic reprogramming. When treatment is discontinued, these pharmacological effects diminish, allowing many of the underlying physiological drivers of energy intake to re-emerge.

One of the most widely cited investigations of this phenomenon is the STEP-4 clinical trial, which evaluated the effects of withdrawing semaglutide after an initial treatment phase. Participants first received semaglutide for 20 weeks and achieved an average 10.6% reduction in body weight. They were then randomly assigned either to continue semaglutide or switch to placebo.

Over the subsequent 48 weeks:

• Participants who continued semaglutide lost an additional ~7.9% of body weight.

• Participants who switched to placebo regained approximately 6.9% of body weight despite ongoing lifestyle interventions.

These findings demonstrate that cessation of GLP-1 therapy is associated with a partial reversal of treatment-induced weight loss.

Similar findings have been reported in studies evaluating tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. In the SURMOUNT-4 trial, individuals who discontinued tirzepatide after significant weight reduction experienced progressive weight regain, whereas those who continued therapy maintained or further reduced body weight.

Together, these studies reinforce the concept that continued receptor activation may be necessary to sustain appetite suppression and long-term weight loss.

Physiological Drivers of Weight Regain

Weight regain following treatment discontinuation appears to be influenced by several interconnected biological mechanisms.

1. Restoration of Appetite Signalling

GLP-1 receptor agonists suppress appetite through central nervous system pathways involving the hypothalamus, hindbrain, and reward centres such as the nucleus accumbens. When pharmacological stimulation of these receptors stops, appetite signals gradually return to baseline levels, often resulting in increased hunger and greater caloric intake.

2. Hormonal Adaptations to Weight Loss

Weight reduction itself triggers compensatory endocrine responses designed to restore energy balance. These include:

• Increased levels of the hunger hormone ghrelin

• Reduced secretion of satiety hormones

• Alterations in leptin signalling

These hormonal adaptations can persist for extended periods following weight loss and are thought to contribute significantly to long-term weight regain.

3. Metabolic Adaptation

Weight loss is frequently accompanied by a reduction in resting metabolic rate, a phenomenon sometimes referred to as adaptive thermogenesis. As energy expenditure decreases, maintaining a reduced body weight becomes progressively more difficult without sustained behavioural or pharmacological support.

4. Changes in Body Composition

Rapid weight loss may involve reductions in both fat mass and lean body mass. Loss of skeletal muscle can further reduce metabolic rate, which may increase susceptibility to weight regain if nutritional intake and resistance exercise are not carefully maintained.

Implications for Long-Term Weight Management

The available evidence suggests that GLP-1 receptor agonists may function more similarly to chronic disease therapies rather than short-term weight-loss interventions. In this context, obesity is increasingly recognised as a condition requiring long-term management strategies, similar to hypertension or diabetes.

Current research is therefore exploring strategies that may improve long-term weight maintenance after GLP-1 therapy, including:

• Gradual dose tapering rather than abrupt discontinuation

• Combining pharmacotherapy with structured behavioural and nutritional interventions

• Development of next-generation incretin therapies, including dual and triple receptor agonists

Understanding how to maintain weight loss after treatment discontinuation remains an active area of investigation. As incretin-based therapies continue to evolve, identifying effective long-term management strategies will be critical to maximising their clinical benefit.

References

Wilding, J.P.H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity.New England Journal of Medicine, 384, 989-1002.

Rubino, D., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP-4 trial.JAMA, 325(14), 1414-1425.

Jastreboff, A.M., et al. (2022). Tirzepatide once weekly for the treatment of obesity.New England Journal of Medicine, 387, 205-216.

Reiss, A.B., et al. (2025). Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss.Biomolecules, 15(3), 408.

GLP-1 Medications, Fatty Liver and Weight Loss: What the Science Shows

Medications such as Ozempic®, Wegovy®, Mounjaro® and Zepbound® are increasingly used to support weight loss and improve metabolic health. These medications belong to a class of treatments known as incretin-based therapies.

Incretins are natural gut hormones released after eating that help regulate appetite, insulin secretion, and blood glucose levels. Two of the most important incretin hormones are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).

Weight-loss injections such as semaglutide (Ozempic®, Wegovy®) act as GLP-1 receptor agonists, meaning they mimic the action of the natural GLP-1 hormone. Newer medications such as tirzepatide (Mounjaro®, Zepbound®) activate both GLP-1 and GIP receptors, providing dual incretin activity.

While these medications are widely recognised for their ability to reduce appetite and support significant weight loss, research is increasingly showing they may also have important effects on liver health and metabolic disease.

A review by Newsome and Ambery explores how incretin therapies influence liver metabolism and their potential role in managing metabolic liver disease.

Understanding Incretins

Incretins are hormones released from the gastrointestinal tract following food intake. Their primary role is to enhance insulin secretion from pancreatic β-cells in a glucose-dependent manner, helping regulate blood glucose levels after meals.

The two key incretin hormones are:

• GLP-1 (Glucagon-like peptide-1)
• GIP (Glucose-dependent insulinotropic polypeptide)

Beyond insulin regulation, these hormones influence several metabolic processes including:

• Appetite regulation via the brain’s satiety centres

• Gastric emptying

• Lipid metabolism

• Energy balance

Pharmacological incretin therapies mimic or enhance these hormonal pathways to improve metabolic outcomes.

The Liver and Metabolic Disease

The liver plays a central role in metabolic homeostasis. It regulates:

• Glucose production and storage

• Lipid metabolism

• Cholesterol synthesis

• Hormonal signalling

In individuals with obesity or insulin resistance, excess fat can accumulate in the liver. This condition is now known as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), previously referred to as non-alcoholic fatty liver disease (NAFLD).

MASLD is strongly associated with:

• Type 2 diabetes

• Obesity

• Dyslipidaemia

• Increased cardiovascular risk

How GLP-1 and Incretin Therapies Affect the Liver

According to the review by Newsome and Ambery, incretin-based therapies may influence liver health through multiple metabolic mechanisms.

Reduction in Liver Fat

Weight loss achieved through GLP-1 receptor agonists can significantly reduce hepatic steatosis (fat accumulation in the liver). Even moderate weight reduction is associated with measurable improvements in liver fat and metabolic markers.

Improved Insulin Sensitivity

GLP-1 therapies improve insulin secretion and suppress inappropriate glucagon release. Improved glycaemic control reduces metabolic stress on the liver and may reduce hepatic fat production.

Effects on Lipid Metabolism

Incretin signalling can influence lipid metabolism through several pathways including:

• Reduced hepatic lipogenesis (fat production)

• Increased fatty acid oxidation

• Reduced ectopic fat deposition

These mechanisms may contribute to improvements in metabolic liver disease.

Potential Direct Hepatic Effects

While many of the benefits appear related to weight loss and improved metabolic control, researchers are also investigating direct hepatic signalling pathways influenced by incretin therapies, including effects on inflammation, fibrosis and cellular metabolism.

Dual and Triple Incretin Therapies

Newer medications are being developed to target multiple incretin receptors simultaneously.

Examples include:

• Dual GLP-1/GIP agonists

• Triple agonists targeting GLP-1, GIP and glucagon pathways

These therapies aim to enhance metabolic signalling and may produce greater weight loss and improved metabolic outcomes.

Ongoing clinical trials are exploring whether these therapies may also provide additional benefits for metabolic liver disease and cardiovascular risk reduction.

Why Nutrition Support Is Still Essential

Although GLP-1 and incretin-based medications are powerful tools for weight management, nutrition remains a critical component of treatment.

Because these medications suppress appetite, some individuals may unintentionally consume insufficient protein, fibre or micronutrients.

Appropriate nutritional support helps:

• Preserve lean muscle mass during weight loss

• Prevent micronutrient deficiencies

• Support metabolic and liver health

• Improve long-term weight maintenance

A structured nutrition approach ensures that weight loss occurs in a way that supports overall metabolic health rather than simply reducing calorie intake.

Final Thoughts

Incretin-based therapies represent a significant advancement in the treatment of obesity, type 2 diabetes and metabolic disease. As highlighted in the research by Newsome and Ambery, their effects extend beyond appetite regulation to include important influences on liver metabolism and metabolic health.

As these therapies continue to evolve, combining medical treatment with personalised nutrition support remains essential for achieving safe, sustainable and metabolically healthy weight loss.

References

Newsome, P. N., & Ambery, P. (2024).
Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver.
Journal of Hepatology.

Drucker, D. J. (2023).
Mechanisms of Action and Therapeutic Application of GLP-1.
Cell Metabolism.

Wilding, J. P. H., et al. (2021).
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
New England Journal of Medicine.

Jastreboff, A. M., et al. (2022).
Tirzepatide Once Weekly for the Treatment of Obesity.
New England Journal of Medicine.